TSX:EDT • CA8475771033
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SPECTRAL MEDICAL INC (EDT.CA).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.67M -18.54% | 1.598M -4.31% | 2.286M 43.05% | 2.627M 14.92% | 5.035M 91.66% | 17.321M 244.01% | 86.063M 396.87% | 160.49M 86.48% | 223.95M 39.54% | 284.62M 27.09% | 349.28M 22.72% | 437.41M 25.23% | |
| EBITDA YoY % growth | -8.17M 1.57% | -11.518M -40.98% | -12.49M -8.44% | -4.848M 61.18% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.45M 1.74% | -11.736M -38.89% | -12.741M -8.56% | -7.737M 39.28% | -5.445M 29.62% | 2.443M 144.87% | 49.416M 1,922.76% | 100.32M 103.01% | 143.8M 43.34% | 185.54M 29.03% | 229.91M 23.91% | 290.58M 26.39% | |
| Operating Margin | -505.99% | -734.42% | -557.35% | -294.50% | -108.14% | 14.10% | 57.42% | 62.51% | 64.21% | 65.19% | 65.82% | 66.43% | |
| EPS YoY % growth | -0.04 -14.29% | -0.06 -42.70% | N/A -23.87% | -0.17 -142.86% | -0.04 76.47% | 0.00 100.00% | 0.07 | 0.20 183.95% | 0.33 64.98% | 0.45 36.39% | 0.58 26.66% | 0.75 29.84% |
All data in CAD
| Q4 / 25 | Q1 / 26 | |
|---|---|---|
| EPS Q2Q % growth | -0.02 | -0.01 75.81% |
| Revenue Q2Q % growth | 546.41K -15.29% | 761.54K 36.81% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -3.657M -41.59% | -1.766M 52.79% |
All data in CAD
6 analysts have analysed EDT.CA and the average price target is 3.16 CAD. This implies a price increase of 141.37% is expected in the next year compared to the current price of 1.31.
SPECTRAL MEDICAL INC (EDT.CA) will report earnings on 2026-03-26, before the market open.
The consensus EPS estimate for the next earnings of SPECTRAL MEDICAL INC (EDT.CA) is -0.02 CAD and the consensus revenue estimate is 546.41K CAD.
The consensus rating for SPECTRAL MEDICAL INC (EDT.CA) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.